Should You Continue to Retain MYGN Stock in Your Portfolio? [Yahoo! Finance]
Myriad Genetics, Inc. (MYGN)
Last myriad genetics, inc. earnings: 2/6 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
myriad.com/news-center/investor-information
Company Research
Source: Yahoo! Finance
MYGN is making notable strides in its key strategic areas, which is poised to help it grow in the upcoming quarters. New product introductions and enhancements are gaining traction with customers. There is growing optimism about the company's huge potential in the oncology space. Meanwhile, the impacts of macroeconomic pressure and fierce rivalry can be worrisome for Myriad Genetics' performance. In the past year, this Zacks Rank #3 (Hold) company has outperformed both the industry and the S&P 500 composite. Shares have surged 63.8% compared with the industry's 0.7% rise and the S&P 500's gain of 25.7%. The renowned genetic testing and precision medicine company has a market capitalization of $2.51 billion. MYGN's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 213.4%. Let's delve deeper. Tailwinds for MYGN Progress With Three Strategic Priorities: Myriad Genetics is advancing in developing top-quality products, building
Show less
Read more
Impact Snapshot
Event Time:
MYGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MYGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MYGN alerts
High impacting Myriad Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
MYGN
News
- Myriad Genetics, Inc. (NASDAQ: MYGN) is now covered by analysts at Morgan Stanley. They set an "equal weight" rating and a $32.00 price target on the stock.MarketBeat
- Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual ConferenceGlobeNewswire
- Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]Yahoo! Finance
- Myriad Genetics to Host Investor Event on October 9, 2024GlobeNewswire
- New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues [Yahoo! Finance]Yahoo! Finance
MYGN
Earnings
- 8/6/24 - Beat
MYGN
Sec Filings
- 9/16/24 - Form 144
- 9/12/24 - Form 4
- 9/12/24 - Form 4
- MYGN's page on the SEC website